In 2014, Joon Y. Lee, professor of orthopedic surgery at the University of Pittsburgh School of Medicine, performed two surgeries that would go on to change the landscape of UPMC’s musculoskeletal research.

The patient’s name was Orland Bethel, and the 90-year-old founder of the Hillandale Farms in Greensburg. He had developed spinal stenosis, a painful condition that affects the nerves of the spinal cord. After consulting with six other orthopaedic surgeons, Bethel found Lee, who could perform the minimally invasive procedure that Bethel was searching for.

To show his appreciation for the surgeon and UPMC, Bethel gifted an initial $2 million in 2019 to establish Lee’s current position, the Orland Bethel Professorship in Spinal Surgery. By 2026, the Bethel family’s donations total $99 million, which have funded the creation of the Bethel Musculoskeletal Research Center, an initiative dedicated to better understanding and treating musculoskeletal (MSK) diseases and disorders.

“Orland Bethel is changing the landscape of what we know about musculoskeletal disease and supporting critical work that will lead to better treatments,” Pitt Chancellor Joan Gabel said in a statement about Bethel’s donation of $53.5 million, announced in January. “This gift will improve the lives of countless individuals who suffer pain and limited mobility.”

Advertise with us

The BMRC is home to 11 specialized research laboratories, which study spine, cartilage, tendon and muscle — and, in the future, bone and metabolism — through clinical research and patient care. It also funds several student fellowships, from the high school to postdoctoral level, one of which is the 3-year-old Bethel Fellows Program, which supports four to six early career scientists annually.

Orland Bethel, founder of egg producer Hillandale Farms, has gifted a total $99 million to Pitt and UPMC to further understanding and treatment of musculoskeletal diseases and disorders. (Courtesy of University of Pittsburgh)

The biobank

Of Bethel’s total donations, $18.3 million was dedicated to the founding of the BRMC Biobank, a massive collection of surgical biospecimens, or discarded tissues from surgery patients, that UPMC researchers store for later study. The biobank also includes blood, imaging and anonymous health profiles, acting as a sort of database for medical research.

The goal, said Lee, who is executive director of the Bethel MSK Research Center, is to better understand why patients contract different types of musculoskeletal diseases. For example, one of the challenges of treating osteoporosis is predicting who is at the highest risk for developing it; research using anonymous patient profiles and collected tissue samples can help to develop better prevention and treatment methods for the disease.

The biobank has obtained more than 18,000 specimens from 524 consented surgical patients, making it one of the largest MSK biobanks in the world.

“The comprehensive nature of the biobank, to my knowledge, is the only one that is in existence in the MSK realm,” Lee said. “There are other biobanks that are much larger, that have been around much longer. … But in the MSK domain, we are the first and the largest.”

Advertise with us

Lee said it is the unique collaborative environment between the University of Pittsburgh and UPMC that allows for the biobank to be so effective in its collection of data.

“The patients that come through UPMC to get their care are the core center of how we build this biobank,” Lee said. “The biobank can’t exist without UPMC and clinicians [who work] with patients to collect their tissues and [use] their generosity to do research.”

The arthroplasty lab

The BRMC Biobank is only one piece of the MSK research that Bethel’s grant helps to support.

The Arthroplasty Design and Outcomes Lab is making medical and engineering breakthroughs on multiple fronts.

Headed by Kenneth Urish, an adult reconstructive and arthroplasty orthopaedic surgeon, the lab performs hip and knee replacement surgeries and develops innovative treatments for post-surgical implant complications.

Advertise with us

“It’s the best job in the world,”Urish said. “It’s so much fun because [my patients] come back in a month and say, ‘It’s amazing. My pain’s gone. I don’t know why I didn’t do this such a long time ago.’ It’s just such a great group of people.”

Kenneth Urish, a reconstructive orthopaedic surgeon with UPMC, is director of the Arthroplasty Design and Outcomes Lab.(UPMC)

One specialty of the lab: acute infection.

Although there is only a 2% risk of infection in joint implants, chronic infection accounts for around 30% of knee implant failures, according to Urish. An implant failure from chronic infection occurs when the primary treatments do not work and the implant has to be taken out. On the research side, one of the primary goals of the arthroplasty lab is to develop better treatments for infection.

One such solution is the collaboration between UPMC and Peptilogics, a biotech company on the South Side that has developed an antimicrobial peptide therapeutic for implant infections. Urish is a key part of the treatment research, leading clinical trials at the lab.

Urish described the treatment as the “newest stage of antimicrobials since carbapenems,” a type of antibiotics approved by the FDA in 1984.

Advertise with us

The lab is also developing a new antibiotic delivery device for chronic infection, which lowers the typical treatment timeline of three to nine months to one week.

“There’s lower rates of failure and, in the really hard infections, it drastically improves outcomes,” Urish said.

In the case of last resort, around 0.01% of post-surgical infections, Urish said, the lab is experimenting with a new treatment method that uses bacteriophage — a virus that targets select bacteria — as an antibiotic. This type of therapy is becoming an increasingly common alternative with drug-resistant bacteria. Although the treatment is not yet approved by the FDA, the lab is seeing success with clinical trials under expanded-access FDA provisions.

One patient, referred to the lab by an out-of-town physician, became the lab’s first to undergo bacteriophage — or phage — treatment, after being on IV antibiotics for two years. By the end of treatment, Urish said, the patient was receiving injections once every six months.

“This is what we’ve become specialized in,” Urish said. “We’re the last stop, when everything else doesn’t work anymore.”

Advertise with us

The future of MSK research

Lee and the Bethel Musculoskeletal Research Center are currently working toward establishing a branch, called the Innovations Pathway, to make it easier for investigators who have come up with an innovative product or treatment for a disease to patent and market their products to the medical industry. Lee hopes it will provide a more supportive way for innovators to navigate the business side of treatment development.

And the biobank is expanding into pediatrics research. Most musculoskeletal diseases in children are caused by trauma or congenital issues, said Lee, and the biobank has begun collecting children’s tissues in order to study the causes of these diseases.

Also coming up: The annual BRMC research symposium, set for Sept. 25, includes researchers and Bethel fellows and a keynote from author Emily Calandrelli.

Abby Lipoid is a freelance writer based in Pittsburgh.